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to overcome structural and functional 
constraints, with high costs for the viral 
fitness (7–9). On the other hand, a  
number of immunological factors shape 
the virus-specific, HLA-B*27-restricted 
CTL responses including polyfunctional-
ity, superior functional avidity, selection 
of specific TCR clonotypes associated 
with a higher cross-reactivity, lower 
sensitivity to regulatory T cell-mediated 
suppression as well as a rapid and effi-
cient processing of the proper epitopes 
(2,6,10–13). Another aspect to consider is 
the level of promiscuity within the same 
or different supertypes (14). Few stud-
ies have extensively and systematically 
approached this topic (15,16). In addi-
tion, discordant results make difficult to 
determine whether epitope promiscuity 
by two or more HLA-B class I molecules 
is frequent (95% in ref 15) or relatively 
uncommon (3% in ref 16). HLA-B*27 
and -B*57 have been correlated to a more 
“private” peptide repertoire (82% and 
protective and some, such as the HLA-B*27 
and -B*57, rank at the top given their  
superior capacity of viral control (3–5).
Our understanding of their association 
with a slow progression to AIDS (4,5) 
and with a high rate of spontaneous 
clearance of hepatitis C virus is still in-
complete (6,7). So far, either virological 
or immunological mechanisms have 
been postulated. Viral escape from HLA-
B*27-restricted CTL responses directed 
against HIV- and HCV-immunodomi-
nant epitopes is unlike since it requires 
several and compensatory mutations 
iNTRODUcTiON
In the context of the adaptive immunity, 
HLA class I-restricted CD8+ cytotoxic 
T lymphocytes (CTL) are pivotal in con-
trolling viral infections. They express 
αβ T-cell receptors (TCRs) recognizing 
short viral antigens that are presented 
on the infected cells in association with 
HLA encoded class I heavy chain and 
β2-microglobulin.
A major role of HLA-B alleles in  
mediating the most effective antiviral  
immunity has been reported (1,2). How-
ever, not all HLA-B alleles are equally 
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Autologous B lymphoblastoid cell 
lines (B-LCLs) were generated by in vitro 
B cell immortalization with the standard 
type I EBV isolate B95.8 (22).
Cells were cultured in heat-inactivated 
10% fetal bovine serum (FBS; Sigma  
Aldrich)/RPMI 1640 medium (Euroclone 
Spa) supplemented with 2 mmol/L 
L-glutamine, 100 U/mL penicillin,  
100 μg/mL streptomycin.
C1R and T2 stable transfectants were 
maintained in medium added with G418 
(800 μg/mL) or hygromycin B (200 μg/mL), 
respectively.
PBMc stimulation
PBMC (4 × 106) separated from whole 
blood by density gradient separation 
(Cedarlane Laboratories Ltd.) were incu-
bated with the indicated peptides  
(20 μmol/L) and cultured for 12 d at  
1.5 × 106 cells/mL in 5% FBS/RPMI com-
plete medium, and 10 U/mL of human 
recombinant interleukin 2 (IL2) (Roche 
Applied Science). On d 3 and 9, fresh 
medium containing 20 U/mL of IL2 was 
replenished. After 12 d of antigen pulsing, 
PBMC were used for pentamer staining 
and, on d 14, used for intracellular IFNγ 
staining.
Pentamer staining
B*0702/pEBNA3A and B*2705/
pEBNA3C MHC class I pentamers phy-
coerythrin-conjugated were purchased 
by Proimmune. Twelve days after pep-
tide stimulation, 0.5 × 106 PBMCs were 
treated with pentamers for 10’ at RT. 
Cells were then labeled with anti-CD8-
FITC (mouse anti-human CD8-FITC- 
conjugated, BioLegend) for 20’ on ice. 
The samples were acquired by a FACS-
Calibur flow cytometer (Becton Dickinson) 
and analyzed by FlowJo software (Tree 
Star Inc.).
intracellular iFNf staining
Briefly, C1R transfectants were incu-
bated ON with pEBNA3A or pEBNA3C 
(30 μmol/L) or with medium alone and 
then plated with antigen-stimulated 
PBMC at 5:1 PBMC/APC ratio. After 2 h, 
the cells were treated with brefeldin A 
according to modified New York criteria. 
The HLA-B*27 subtype was determined 
by serological analysis using ME1 mAb 
(specificity: HLA-B*27; -B*07; -B*42; -B*67; 
-B*73 and -B*w22) and genomic analysis. 
The positivity to HLA-B*07 was checked 
by BB7.1 (specificity: HLA-B*07). The 
study received the approval by the Ethics 
Committee of the University of Cagliari 
(365/09/CE). All subjects provided writ-
ten informed consent prior to enrolment.
synthetic Peptides and chimeric 
Protein
pEBNA3C (RRIYDLIEL; aa 258-266) 
and pEBNA3A (RPPIFIRRL; aa 379–387) 
which are immunodominant EBV- 
epitopes restricted by HLA-B*27 (28) and 
by HLA-B*07 (26,27) respectively, have 
been used in this study. For the bind-
ing assay, a self-peptide restricted by 
HLA-B*27 (TIS, RRLPIFSRL) (29) and an 
immunodominant CMV-epitope HLA-
A*02-restricted (pp65, NLVPMVATV) 
were included. A modified version of 
pEBNA3A (APPIFIRRL) has been also 
analyzed. Peptides (purity > 95%) were 
purchased by Aurogene. The chimeric 
protein containing EBNA3A epitope 
was generated using pTAT-HA expres-
sion vector according to the procedure 
already described (30). To generate the 
EBNA3A epitope, the following primers 
have been used:
forward: 5′-caag tactcgagaactgagaa 
gcaggccaccaatattcataaggaggctgaga-3′;
reverse: 5′-ccgaggaggccctctgttgattggtgt 
tccctccacttctcagcctccttatgaatat-3′.
Following DNA sequencing of the 
recombinant construct, the production, 
purification and detection of the chimeric 
protein have been done as previously 
described (31).
cell Lines
TAP-defective CEM 174.T2 cells 
(ATCC number: CRL-1992™) (32) 
and HMy2.C1R cells (ATCC number: 
CRL-1993™) (33), stably expressing 
B*2705, B*2709 (T2 and C1R cells) or 
B*0702, A*0201 (C1R cells) were used. 
C1R.B*0702 transfectants were a gift 
from Dr. JA LÓpez De Castro.
56%, respectively) in comparison to other 
HLA class I alleles (14) suggesting that a 
low degree of promiscuity has protective 
effects. Overall, these data indicate that 
HLA-B*27 and -B*57 alleles rarely share 
their own peptidome with other HLA 
molecules. Whether these alleles bind 
and present immunodominant peptides 
restricted by other HLA-class I molecules 
has never been convincingly explored.
Noteworthy, both HLA-B*27 and -B*57 
family of alleles are associated with the 
susceptibility to autoimmune diseases, 
namely Ankylosing Spondylitis (AS) and 
Psoriasis, respectively (17–20). Therefore, 
it is conceivable that a common ground 
underlies the superior viral immune 
defense on the one hand and the propen-
sity to autoimmunity on the other. The 
antigen presentation performed by such 
HLA-B supertypes could be a key event 
(7,21). A way to validate this hypothesis 
could be a functional comparison between 
very close pair of alleles, like as the B*2705 
and the B*2709, which have a single amino 
acid substitution (Asp116His) (22) but are 
differently associated with AS (19,23–25).
Here, we show that the B*2705, but 
not the non-AS-associated HLA-B*2709, 
presents an EBV-derived immunodom-
inant epitope (pEBNA3A; RPPIFIRRL) 
restricted by the HLA-B*0702 (26,27) 
and therefore devoid of the optimal B*27 
binding motif, evoking a vigorous CD8+ T  
cell response in B*2705/B*07-double 
positive as well as in B*2705-single posi-
tive carriers, either AS-patients or healthy 
donors (HD). The occurrence of prefer-
ential TCRBV and TCRBJ gene segments 
and the sharing of similar CDR3β regions 
by the B*2705-restricted pEBNA3A- 
responsive CTLs support the involvement 
of the TCR in such recognition.
MATERiALs AND METhODs
study subjects
Four HLA-B*07/B*2705-double positive 
AS-patients, thirty-eight HLA-B*2705- 
positive subjects (31 AS-patients and 
seven HD) and eight HLA-B*2709- 
positive controls were enrolled in this 
study. Diagnosis of AS has been made 
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restricted versus HLA-B*0702-restricted 
CTLs. These two HLA class I alleles 
share 94% homology; nonetheless, the 
B*2705 is strongly AS-associated while 
the B*0702 plays a protective role (37). To 
overcome the inter-individual variability, 
we selected, a B*2705/B*0702-double 
positive patient with AS (Don 1.05.07). 
Freshly isolated PBMC were incubated 
with pEBNA3C or pEBNA3A, that are 
well known EBV-derived immunodom-
inant epitopes restricted by HLA-B*2705 
(28) or HLA-B*0702 (26,27), respectively. 
CD8+ T cells specific for both epitopes 
were present, as assessed using B*2705/
pEBNA3C and B*0702/pEBNA3A 
pentamers (0.265% for pEBNA3C- and 
0.826% for pEBNA3A-reactive cells)  
(Figure 1A).
statistics
Data obtained by IFNγ-production 
assays from antigen-stimulated PBMCs 
from B*2705-positive versus B*2709- 
positive carriers were compared by 
Fisher’s two-tailed exact test (Figure 3C) 
and Mann–Whitney U-test (Supple-
mentary Figure S3). A p value < 0.05 was 
 considered statistically significant.
All supplementary materials are available 
online at www.molmed.org.
REsULTs
Atypical Antigen Presentation  
by hLA-B*2705 Molecules
Our initial aim was to compare the 
immunological properties of HLA-B*2705-
(10 μg/mL) at 37°C for 16h. Cells were 
stained with the anti-CD8-FITC mAb, 
20’ on ice, fixed with 4% paraformalde-
hyde 20’ on ice, permeabilized with 1% 
BSA/0.1% saponin in PBS 1 × for 5′ at 
RT and then resuspended in 2% parafor-
maldehyde/1% BSA. Finally, cells were 
stained by an anti-IFNγ-APC mAb (Bio-
Legend) 20’ RT and analyzed by FlowJo 
software.
cTL Generation
PBMC were stimulated with pEBNA3A 
or pEBNA3C (30 μmol/L) in 5% FBS/
RPMI 1640. After 24 h, PBMC were 
washed and 10 U/mL of IL2 were added 
to the culture medium. On d 10, PBMC 
were depleted of the CD4+ T cell fraction 
by Dynabeads M-450 CD4+ (Dynal ASA) 
and the isolated CD8+ T cells were seeded 
at 1 × 105 cells/well in 96-well plates in 
the presence of antigen-pulsed (over-
night at 30 μmol/L), γ-irradiated (200 
Gy) autologous B-LCLs (CD8+ T cells/
APC ratio 2:1) and 20 U/mL of IL2. After 
3 rounds of stimulation, cell antigen 
specificity was assayed in a standard 51Cr- 
release assay as previously described (34).
TcR Gene Usage Analysis
Total RNA was isolated from CD8+ T 
cells using the Trizol reagent (Invitro-
gen) according to the manufacturer’s 
instructions. Purified RNA was reverse- 
transcribed using the High- Capacity 
cDNA Reverse Transcription kit 
( Applied Biosystems). cDNA was used 
to amplify the TCRBV family chains 
with 24 TRBV specific primers as al-
ready described (35). Specific products 
were purified from gel (QIAquick, Qia-
gen spa) and underwent direct sequenc-
ing. The IMGT nomenclature has been 
adopted for TCRBV (36).
T2.B*27 stabilization Assay
ME1 mAb and an IgG1 isotype control 
antibody were employed to assess the 
capability of the peptide under study  
to stabilize the cell surface B*2705 or  
B*2709 molecules on T2 transfectants  
(32) according to the procedure previously 
described (34).
Figure 1. B*2705 can promiscuously present the B*0702-restricted EBNA3A epitope to  
CD8+ T cells from a B*2705/B*0702 positive AS patient (Don 1.05.07). (A) Flow cytometry 
plots for HLA-B*2705/pEBNA3C (left panel) and HLA-B*0702/pEBNA3A (right panel) pen-
tamer staining within CD8+ T cells of PBMCs cultured for 12 d with pEBNA3C and pEBNA3A 
synthetic peptides (20 μmol/L), respectively. Numbers indicate the percentage of pen-
tamer-positive CD8+ T cells. Smaller panels show flow cytometry profiles of pEBNA3C- (left) 
or pEBNA3A-stimulated (right) PBMCs for staining with an irrelevant pentamer. (B) Detec-
tion of intracellular IFNγ production by PBMCs stimulated with pEBNA3C or pEBNA3A for 
14 d and then re-stimulated by the indicated, untreated or peptide-pulsed C1R trans-
fectants (30 μmol/L). Numbers represent the percentage of IFNγ-producing CD8+ T cells. 
(C) Assessment of cytotoxicity by representative pEBNA3A- (top) and pEBNA3C- (bottom) 
stimulated CTL lines against HLA-B*0702, -B*2705, -B*2709 C1R transfectants used as target 
cells. E/T ratio was 20:1. Bars represent the mean percentage of specific lysis ± SEM of 
three separate experiments.
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could reside in a different binding affin-
ity. However, available MHC binding 
prediction tools (http://www.cbs.dtu.dk/ 
services/Net MHCcons/) failed to identify 
any binding for pEBNA3A to either B*27 
allele. Stabilization assays on T2.B*2705 
or T2.B*2709 transfectants (32) incubated 
with increasing amount of pEBNA3A, or 
TIS as positive reference (29), confirmed 
no detectable binding of pEBNA3A to B*27 
alleles (Supplementary Figure S2).
B*2705- But Not B*2709-Positive 
carriers Elicit pEBNA3A-Driven cD8+ T 
cell Reactivity
The results obtained in three out of 
four B*07/B*2705-double positive indi-
viduals clearly indicated a promiscuous 
presentation of pEBNA3A. We therefore 
asked whether this epitope could elicit a 
specific T cell response in B*2705- 
positive/B*07-negative individuals. 
it is not shared by the closely related, 
non-disease associated B*2709.
We have previously characterized an 
alternative antigen presentation pathway 
exploited by HLA-B*27, based on the 
use of intracellularly targeted chimeric 
proteins carrying viral epitopes (30,31). 
We asked whether pEBNA3A could be 
presented by HLA-B*27 through this 
endogenous pathway. Accordingly, 
C1R.B transfectants were transduced 
by the chimeric protein harbouring the 
pEBNA3A sequence (Figure 2B) and 
used as targets of pEBNA3A-stimulated 
CTLs in cytotoxicity assays. Again, the 
pEBNA3A-chimeric protein made both 
C1R.B*0702 and C1R.B*2705 transfectants 
susceptible to specific lysis whereas nei-
ther C1R.B*2709 or C1R.A*0201 could 
present the epitope (Figure 2C).
A possible explanation for the  
discordant behavior of B*2705 and B*2709 
After 14 d, antigen-stimulated cells 
were re-exposed to the epitopes by 
co-culture with the peptide-pulsed 
C1R.B*0702, C1R.B*2705 or C1R.B*2709 
transfectants and IFNγ-production 
was measured in the CD8+ T cell 
fraction. Figure 1B shows that pEB-
NA3C-exposed PBMCs were activated, 
as expected, only by pEBNA3C- 
prepulsed C1R.B*2705 and C1R.B*2709 
cells, whereas no IFNγ-producing cells 
were detected when pEBNA3C-loaded 
C1R.B*0702 were used as control. In 
contrast, pEBNA3A-stimulated PBMCs 
produced IFNγ either when pEBNA3A 
was presented by either C1R.B*0702 
cells (1.84% of IFNγ-producing CD8+ 
T cells) or C1R.B*2705 transfectants 
(2.9% of IFNγ-producing CD8+ T cells) 
but not when presented by C1R.B*2709 
transfectants (Figure 1B). To further 
explore this unexpected finding, the cy-
totoxic activity of pEBNA3A-stimulated 
cells against C1R transfectants was veri-
fied. Cytotoxicity occurred upon presen-
tation of pEBNA3A by HLA-B*0702 and 
B*2705 but not by B*2709 (Figure 1C). 
In parallel, we tested pEBNA3C-specific 
CTL lines which, as expected, lysed 
both the C1R.B*2705 and C1R.B*2709 
transfectants but not the HLA-B*0702 
(Figure 1C). The pEBNA3A- and pEB-
NA3C-responsive CTL lines, although 
oligoclonal, did not display reciprocal 
cross-reactivity (data not shown). To 
exclude that the atypical presentation of 
B*07-restricted epitopes by HLA-B*27 
molecules was an occasional event, 
three more B*2705/B*07-double posi-
tive individuals were analyzed. Data 
from two other AS-patients, Don 2.05.07 
and Don 3.05.07 (Figure 2 and Supple-
mentary Figure S1, respectively) were 
consistent with the previous results. 
The fourth patient (Don 4.05.07) did not 
respond to pEBNA3A antigen either in 
B*07 or in B*27 context of presentation 
(data not shown). The results indicate 
that the promiscuous presentation of 
B*07 epitope is a common feature, oc-
curring in 3/4 of the AS-patients ana-
lyzed. Moreover, it is selective for the 
AS-associated B*2705 molecule, since 
Figure 2. Uncanonical pEBNA3A presentation by HLA-B*2705 in a second B*2705/B*07- 
positive AS patient. (A) Measurement of IFNγ secretion in PBMCs from Don 2.05.07 stimulated 
with pEBNA3A for 14 d and then re-stimulated by untreated or pEBNA3A-pulsed C1R trans-
fectants. Numbers represent the percentage of IFNγ-producing CD8+ T cells. (B) Schematic 
representation of the pEBNA3A-chimeric protein showing the location at the N-terminus of 
6-His tag, the TAT transduction domain and the hemoagglutinin (HA) tag followed by the 
nucleoprotein of influenza A virus protein in which the sequence of EBNA3A epitope has 
been inserted. (C) 51Cr-release assay in which cytolytic effector functions of a representa-
tive pEBNA3A-stimulated CTL line was tested against C1R transfected cells, pre-pulsed with 
pEBNA3A provided as synthetic peptide (30 μmol/L) or transduced by the chimeric protein 
carrying EBNA3A epitope (1 μmol/L). E/T ratio was 20:1. Bars represent the mean percent-
age of specific lysis ± SEM of three separate experiments.
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have a comparable functional avidity. 
These data have been further validated 
by cytotoxicity assays performed on 
these same cells following CD8+ T cell 
purification. Once again, at higher antigen 
concentrations (range 0.3–30 μmol/L), spe-
cific lysis was greater for pEBNA3A- than 
pEBNA3C-stimulated CTLs (Figure 4B) 
while the opposite occurred at the lowest 
concentration (0.03 μmol/L).
To understand whether the N-terminal 
Arg in pEBNA3A acts as principal an-
chor fitting into the B-pocket, we tested 
a modified version of the peptide with 
staining test upon re-stimulation with 
C1R.B*2705 transfectants. Figure 4A 
shows representative data obtained from 
an AS-patient (Don 15.05): at the higher 
peptide concentrations (3 and 30 μmol/L), 
the percentage of IFNγ-secreting CD8+ T 
cells is greater for pEBNA3A than for 
pEBNA3C (5.74% versus 3.42% and 
3.29% versus 2.7%, respectively). This 
trend reversed at the lowest peptide 
concentration (0.3 μmol/L) (0.37% ver-
sus 2.1%) but yet, the detection of some 
pEBNA3A-responsive CD8+ T cells 
suggested that these virus-specific CTLs 
PBMC from 38 HLA-B*2705-positive 
donors (31 patients with AS and 7 HD) 
were propagated in the presence of 
pEBNA3A. Following re-stimulation by 
pEBNA3A-pulsed C1R transfectants, 
antigen-specific IFNγ-production was 
measured. The results from one rep-
resentative B*2705-positive individual 
(Don 10.05) revealed the presence of 
IFNγ-producing CD8+ T cells (0.899%) 
when the peptide was presented by 
B*2705 but no by B*2709 or B*0702 mole-
cules (Figure 3A). A parallel stimulation 
with pEBNA3C yielded an expansion 
of IFNγ-producing CD8+ T cells in the 
B*27 context of presentation (1.05% by 
B*2705 and 1.38% by B*2709 allele). The 
representative B*2709 individual (Don 
6.09) did not respond to pEBNA3A while 
displaying reactivity toward pEBNA3C 
presented by either B*2705 or B*2709 
(Figure 3A).
Cytotoxicity assays performed with 
pEBNA3A- and pEBNA3C-specific CTLs 
mirrored the results obtained by intra-
cellular IFNγ staining (Figure 3B). Twen-
ty-one B*2705 carriers (18 AS-patients 
and 3 HD) out of 38 were found pEB-
NA3A-responsive (55.3%) exclusively in 
the B*2705 context. On the contrary, none 
of the eight B*2709 individuals analyzed 
showed pEBNA3A-reactivity mak-
ing significant the difference between 
B*2705- and B*2709-positive EBNA3A re-
sponders (p = 0.0049) (Figure 3C). Func-
tional data obtained by intracellular IFNγ 
staining after pEBNA3A stimulation in 
all B*2705 and B*2709 carriers analyzed 
are shown in supplementary figure S3. 
Thus, pEBNA3A could be efficiently 
presented by B*2705 molecules and the 
repertoire of B*2705-positive individuals, 
independently of the disease, comprises 
CD8+ T cell precursors triggered by the 
non-canonical pEBNA3A/B*2705 com-
plex. The same does not occur in the 
B*2709 context of presentation.
To evaluate the functional avidity 
of pEBNA3A-specific CD8+ T cells of 
B*2705-positive/B*07-negative subjects, 
PBMC were expanded in presence of 
pEBNA3A or pEBNA3C, and analyzed 
in a dose-response intracellular IFNγ 
Figure 3. B*2705 but not B*2709-positive carriers react toward the HLA-B*0702-restricted 
EBNA3A epitope. (A) Detection of intracellular IFNγ production by PBMCs from a B*2705 
positive/B*07 negative subject (Don 10.05) (left) or a B*2709 positive/B*07 negative sub-
ject (Don 6.09) (right) activated with pEBNA3A or pEBNA3C peptide for 14 d and then 
re-stimulated by the indicated, untreated or peptide-pulsed C1R transfectants. Numbers 
represent the percentage of IFNγ-producing CD8+ T cells. (B) Cytotoxic activity by rep-
resentative pEBNA3A- (top) and pEBNA3C- (bottom) stimulated CTL lines from the same 
individuals as in (A) toward C1R transfectants used as target cells. E/T ratio was 20:1. Bars 
represent the mean percentage of specific lysis ± SEM of three separate experiments. 
(C) CD8+ T cell responses to EBNA3A detected by IFNγ production analyzed in 38 B*2705 
carriers (31 patients with AS and 7 healthy controls) and in 8 B*2709 healthy donors. Twen-
ty-one out of 38 B*2705 and no subject out of 8 B*2709 individuals show reactivity against 
EBNA3A antigen (p value = 0.0049 calculated by Fisher’s two-tailed exact test).
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pAla1 instead of pArg1. Functional 
data by EBNA3A-stimulated PBMC 
from a B*2705-positive patient with AS 
(Don 31.05) displayed substantially no 
production of IFNγ upon re-activation 
by C1R.B*2705 pulsed by the modified 
peptide pAla1-EBNA3A at increasing 
peptide concentrations (Figure S4). This 
result was replicated by PBMCs from 
other two B*2705-positive patients with 
AS (data not shown).
identification of shared TcR a-chain  
Motifs implicated in B*2705/pEBNA3A 
And B*0702/pEBNA3A complex 
Recognition
We then verified whether common 
TCR β-chain motifs were used to rec-
ognize pEBNA3A either in association 
with B*2705 or B*07. The analysis was 
performed on repeatedly antigen- 
stimulated CD8+ T cell lines (four 
to five rounds of stimulation) that, 
although oligoclonal, were highly en-
riched for pEBNA3A-specific T cells. 
The assessment was conducted on four 
B*2705 carriers, two B*2705/B*07 subjects 
and three B*07-positive donors which 
were strongly pEBNA3A-reactive. For 
each subject, only the most abundantly 
expressed TCRBV chains underwent 
direct sequencing and a further selection 
was made to retrieve only unambiguous 
signals. Table 1 reports the most rele-
vant sequences. T cells from two B*2705 
AS-patients (Don 10.05 and Don 1.05) 
shared an almost identical TCR β-chain 
(TRBV24-1TRBJ2-1) with a single differ-
ence from Ser(S) to Gln(Q) in the CDR3 
region (DLGS/QGVG). A similar TCR 
β-chain sequence was also expanded in 
T cells of a third B*2705 AS-patient (Don 
17.05) showing an homologous CDR3 
motif (DMGQN), a same BJ2-1 segment 
but BV4-1 instead of the BV24-1. Notewor-
thy, the BV4-1 segment was used by the 
public TCR β-chain (TRBV4-1TRBJ2-7) 
found in CTLs of a B*2705/B*07 AS- 
patient (Don 1.05.07) as well as in a 
B*07-positive HD (Don 2.07) and thus, 
presumably, selected as interacting with 
the canonical B*07/pEBNA3A com-
plex. Consistent with these findings, we 
Table 1. TCR β-chain sequences of pEBNA3A-responsive CTL lines.
Donor TRBV CDR3 TRBJ
Pt B*27 (Don 10.05) 24-1 CATSDLGSGVGNEQF 2-1
Pt B*27 (Don 1.05) 24-1 CATSDLGQGVGNEQF 2-1
Pt B*27 (Don 17.05) 4-1 CASSQDMGQNNEQF 2-1
Pt B*27/B*07 (Don 1.05.07) 4-1 CASSQETGSYEQY 2-7
HD B*07 (Don 2.07) 4-1 CASSQETGSYEQY 2-7
HD B*07 (Don 3.07) 4-1 CASSQEGGTATYEQY 2-7
HD B*07 (Don 4.07) 4-1 CASSQETGIHTQY 2-3
Pt B*27 (Don 10.05) 4-1 CASSQDGAGGSTDTQY 2-3
Pt B*27 (Don 15.05) 18 CASSEGQVPSKEQF 2-7
Pt B*27 (Don 15.05) 2 CASSEDGENTDTQY 2-3
Pt B*27 (Don 10.05) 6-1 CASSEGAGGSYNEQF 2-1
Pt B*27/B*07 (Don 2.05.07) 3-1 CASSLGTDTQY 2-3
Pt, patient with AS; HD, healthy donor.
The IMGT nomenclature has been used (36).
Figure 4. Functional avidity compared between pEBNA3A- and pEBNA3C-specific CD8+ T 
cells from B*2705 donors. (A) Flow cytometry plots reporting IFNγ production by PBMCs 
from a representative B*2705 AS patient (Don 15.05) expanded in presence of pEBNA3A 
or pEBNA3C (14 d) and exposed to C1R.B*2705 transfectants pulsed with increasing 
concentrations of each peptide before intracellular staining. Numbers indicate the 
percentage of IFNγ-secreting CD8+ T cells. (B) Assessment of the cytolytic activity of rep-
resentative pEBNA3A- and pEBNA3C-stimulated CTL lines from the same donor as in (A). 
C1R.B*2705 transfectants pre-pulsed with serial amounts of the indicated peptide were 
used as targets. E/T ratio was 20:1. Bars represent the mean percentage of specific lysis 
± SEM of three separate experiments.
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Böckmann, personal communication). 
 Overall, although pEBNA3A is appar-
ently a poor B*27 binder, nevertheless 
B*2705 but not B*2709 should be capable 
to form a complex stable enough to in-
duce a CTL response. This is supported 
by the absence of pEBNA3A-specific 
CTLs in B*2709-positive individuals, by 
the lack of allo- and cross-recognition to 
pEBNA3A-B*2709 complexes in either 
B*07/B*2705- or B*2705-positive donors.
An obvious question is how pEBNA3A 
can fit into the B*2705 groove although 
devoid of pArg2, the B*27 dominant 
anchor residue (40,41). The presence of 
a pArg1 might allow the fitting into the 
B-pocket as strongly suggested by the 
abrogation of cell activation when the 
N-terminal Arg was replaced by an Ala. 
Accordingly, a comparable configura-
tion was previously described by X-ray 
crystallography of an octameric peptide 
accommodating itself into the HLA-A2 
groove leaving the A-pocket empty and 
prone to stabilization by water molecules 
(42). Very recently, the characterization of 
Behçet’s disease-associated B*5101 pepti-
dome revealed that major peptide motifs 
are pPro2 or pAla2 (43). Interestingly, 
beside the canonical nonamers and, more 
rarely, decamers with pPro2 or pAla2, 
the peptide elution analysis showed the 
presence of N-terminal truncated versions 
with pPro1 or pAla1. For these peptides, 
it is conceivable a non-canonical binding 
mode with the P1 residue occupying the 
B-pocket. pEBNA3A has a C-terminal Leu 
often found, as PΩ anchor, in the B*2705 
peptidome but even more frequently in 
that of B*2709 (40,41). However, the pres-
ence in pEBNA3A of two Arg preceding 
pLeu9 could favor the peptide stabiliza-
tion in the F-pocket of B*2705 by direct 
or indirect interactions with Asp116. 
This would be not allowed for B*2709 
 possessing His116.
EBNA3A epitope has a proline at 
P2 (pPro2). Noteworthy, the endo-
plasmic reticulum aminopeptidase 1 
and 2, ERAP1 and ERAP2, which trim 
N-terminally extended peptides into the 
ER, display a poor ability to cleave X-Pro 
bonds thus creating a considerable pool 
the capacity to kill pEBNA3A-pulsed 
C1R.B*0702 but not C1R.B*2705 targets 
(data not shown). This suggests the ex-
istence of CTLs with distinct specificities 
and a higher capacity of B*2705-restricted, 
pEBNA3A-responsive CTLs to survive. 
Presumably, a lower functional avidity of 
these CTLs decreases their susceptibility 
to exhaustion and activation-induced cell 
death (2,39).
Noteworthy, pEBNA3A-driven CD8+ 
T cell reactivity has been found in 55.3% 
B*2705-positive subjects analyzed and 
none of the B*2709 donors consistently 
with a sizeable event independent from 
the HLA-B*07.
Therefore, while in B*07/B*2705- 
positive individuals, the effect of the 
promiscuous presentation is unclear, in 
B*2705-positive/B*07-negative subjects 
the existence of long-lived pEBNA3A- 
responsive B*2705-restricted T cells would 
confer a net advantage on viral control. 
A further immunological basis for the 
enhanced protection of B*27 could be its 
engagement in a number of productive 
antiviral responses far greater than ex-
pected and characterized by a wide spec-
trum of functional avidities. Intriguingly, 
these data are consistent with a case of 
allele-dependent epitope promiscuity in 
which being a risk factor to autoimmu-
nity parallels with an enhanced anti-viral 
immune response (7,17–19,21).
Several studies have showed that  
epitope binding affinity is not an abso-
lute predictive factor for the strength and 
frequency of T cell responses (3,39). Para-
doxically, predictive algorithms and sta-
bilization experiments failed to show any 
pEBNA3A binding to B*2705 or B*2709 
molecules. However, computational data 
indicated a higher number of hydrogen 
bonds lost by pEBNA3A/B*2709 com-
pared with pEBNA3A/B*2705 complex 
during a 20 ns molecular dynamics 
simulation, hinting for a more loosely 
embedding of the peptide on the B*2709. 
Moreover, the pEBNA3A/B*2709 com-
plex had a higher fluctuation in the 
α2-helix (residues 170–189) suggest-
ing a higher entropic cost for TCR to 
 interact with such complex (Prof. Rainer 
 retrieved TCR β-chains similar to the 
previous one, bearing the same BV4-1 
and CDR3 motifs, from two other B*07- 
positive HD (Don 3.07 and Don 4.07). It 
is noteworthy that almost all reported se-
quences have a negatively charged amino 
acid (D or E) in the CDR3 region.
DiscUssiON
This study addresses the question 
whether the immunological mechanisms 
whereby HLA-B*27 is protective against 
viruses could overlap with those that 
make it strongly associated with autoim-
munity. In spite of overwhelming data, 
the pathogenic role/s of HLA-B*27 in AS 
and related Spondyloarthritis remains 
uncertain (19).
Our findings show that an EBV-derived 
epitope immunodominant in the HLA-B*07 
context, although lacking of an optimal 
B*27 binding motif, is presented by the 
HLA-B*2705 but not by the non-AS- 
associated B*2709 allele (17–19,23,24). 
Such atypical presentation by B*2705 
evokes T cell-specific responses compa-
rable in magnitude to those elicited by 
pEBNA3A presentation on B*07. It is 
therefore conceivable that during an EBV 
infection, HLA-B*07 and HLA-B*2705 
could actively cooperate or even com-
pete for this same epitope. Noteworthy, 
it has been recently shown that HLA-
B*07 plays a protective role in AS (37). 
Our data allow to speculate that, in an 
HLA-B*2705 context, the co-presence of 
HLA-B*07 could play a favorable role 
subtracting “pathogenic” epitopes to 
HLA-B*27 (18,25). Conversely, it is ques-
tionable whether this epitope sharing is 
beneficial or detrimental to the antiviral 
immunity. This aspect would deserve 
further investigation in view of a vaccine 
design (38).
A further question is whether distinct 
CTL populations do exist, each recogniz-
ing pEBNA3A in a specific HLA context. 
Alternatively cross-reactive antigen-specific 
T cells could mediate the response. In 
this respect, in a B*07/B*2705-positive 
AS-patient (Don 2.05.07), we monitored, 
along the time, the cytotoxicity of 
pEBNA3A-stimulated CTLs that lost 
U N C A N O N I C A L  A N T I G E N  P R E S E N T A T I O N  B Y  H L A - B * 2 7 0 5  M O L E C U L E S
2 2 2  |  T E D E s c h i  E T  A L .  |  M O L  M E D  2 2 : 2 1 5 - 2 2 3 ,  2 0 1 6
4. Carrington M, O’Brien SJ. (2003) The influence 
of HLA genotype on AIDS. Annu. Rev. Med. 
54:535–51.
5. Pereyra F, et al. (2010) The major genetic determi-
nants of HIV-1 control affect HLA class I peptide 
presentation. Science. 330:1551–57.
6. Schmidt J, et al. (2012) Rapid antigen processing 
and presentation of a protective and immu-
nodominant HLA-B*27-restricted hepatitis C 
virus-specific CD8+ T-cell epitope. PLoS Pathog. 
8:e1003042.
7. Neumann-Haefelin C. (2013) HLA-B27-mediated 
protection in HIV and hepatitis C virus infection 
and pathogenesis in spondyloarthritis: two  
sides of the same coin? Curr. Opin. Rheumatol. 
25:426–33.
8. McMichael AJ. (2007) Triple bypass: complicated 
paths to HIV escape. J. Exp. Med. 204:2785–88.
9. Schneidewind A, et al. (2008) Structural and 
functional constraints limit options for cytotoxic 
T-lymphocyte escape in the immunodominant 
HLA-B27-restricted epitope in human immuno-
deficiency virus type 1 capsid. J. Virol.  
82:5594–605.
10. Almeida JR, et al. (2007) Superior control of 
HIV-1 replication by CD8+ T cells is reflected by 
their avidity, polyfunctionality, and clonal  
turnover. J. Exp. Med. 204:2473–85.
11. Berger CT, et al. (2011) High-functional-avidity 
cytotoxic T lymphocyte responses to HLA- 
B-restricted Gag-derived epitopes associated 
with relative HIV control. J. Virol. 85:9334–45.
12. Chen H, et al. (2012) TCR clonotypes modulate 
the protective effect of HLA class I molecules in 
HIV-1 infection. Nat. Immunol. 13:691–700.
13. Elahi S, et al. (2011) Protective HIV-specific CD8+ 
T cells evade Treg cell suppression. Nat. Med. 
17:989–95.
14. Rao X, Hoof I, Costa AI, van Baarle D, Kesmir C. 
(2011) HLA class I allele promiscuity revisited. 
Immunogenetics. 63:691–701.
15. Frahm N, et al. (2007) Extensive HLA class I  
allele promiscuity among viral CTL epitopes. 
Eur. J. Immunol. 37:2419–33.
16. Hillen N, et al. (2008) Essential differences in  
ligand presentation and T cell epitope recog-
nition among HLA molecules of the HLA-B44 
supertype. Eur. J. Immunol. 38:2993–3003.
17. Mathieu A, et al. (2009) The interplay between 
the geographic distribution of HLA-B27 alleles 
and their role in infectious and autoimmune  
diseases: a unifying hypothesis. Autoimmun.  
Rev. 8:420–25.
18. Bowness P. (2015) HLA-B27. Annu. Rev. Immunol. 
33:29–48.
19. Brown MA, Kenna T, Wordsworth BP. (2015) 
Genetics of ankylosing spondylitis—insights into 
pathogenesis. Nat. Rev. Rheumatol. 12:81–91.
20. Feng BJ, et al. (2009) Multiple Loci within the 
major histocompatibility complex confer risk of 
psoriasis. PLoS. Genet. 5:e1000606.
21. Sorrentino R, Böckmann RA, Fiorillo MT.  
(2014) HLA-B27 and antigen presentation: at the 
cONcLUsiON
Taken together, these data disclose the 
capability by B*2705 to behave as restric-
tion element for a peptide discharged as 
binder by all algorithms but abundantly 
produced when ERAP1 is enzymatically 
fully active. This strong flexibility of 
B*2705 groove anticipated by biophysical 
methods and computational analysis 
(21,49,50) and here reinforced by T-cell 
functional data must be regarded as a 
key feature for its enhanced ability to 
mediate viral protection and for association 
with autoimmunity.
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